《新股表現》叮噹健康(09886.HK)暗盤開報15.02元 高上市價逾25%
根據輝立交易平台顯示,將於明早(14日)掛牌的叮噹健康(09886.HK)暗盤開報15.02元,較上市價12元高出約25.2%;現報12.54元,較上市價高4.5%,成交約33萬股。
叮噹健康為生物製內地數字醫療健康到家服務提供商,是次上市全球發售3,353.7萬股,當中香港公開發售佔約一成,公司引入三名基石投資者,包括陽光人壽、Harvest Great Bay Investment SP、Jumpcan International,認購投資額共約3,800萬美元。公司上市料淨集資約3.42億元。聯席保薦人為中金公司及招銀國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.